

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: GOODWIN et al.

Docket No.: 2804-H

Serial No.: 09/079,785

Group Art Unit: 1646

Filed: May 15, 1998

Examiner: L. Spector

For: CD30 LIGAND OLIGOMERS AND POLYPEPTIDES

TRANSMITTAL LETTERAssistant Commissioner for Patents
Washington, D.C. 20231


Sir:

Pursuant to the Examiner's request by telephone on April 11, 2000, a Terminal Disclaimer is submitted herewith for the above-identified application. The Examiner indicated that the obviousness-type double patenting rejection over U.S. Patent 5,753,203, as set forth in the Office Action dated September 13, 1999, is maintained, and that filing of a Terminal Disclaimer would obviate this rejection.

Specifically, the Terminal Disclaimer serves to obviate the obviousness-type double patenting rejection of claims 32-39 of the present application over claims 1-16 of U.S. Patent 5,753,203. The attached Terminal Disclaimer is submitted in order to speed issuance of a patent on the subject application.

Immunex Corporation
51 University Street
Seattle, Washington 98101
(206) 389-4341 (direct line)

Respectfully submitted,

Kathryn A. Anderson
Registration No. 32,172

FEE VALUE ACCOUNTABILITY	
DEPOSIT ACCOUNT NO.	
FEE CODE	VALUE FURNISHED

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Date: April 17, 2000Signed: 

Kathryn A. Anderson



Immunex Corporation
Law Department
51 University Street
Seattle, WA 98101

Phone: 206 587-0430
Fax: 206 233-0644

FAX MESSAGE - PLEASE DELIVER IMMEDIATELY

Send to: Examiner Lorraine Spector
U.S. Patent and Trademark Office
Art Unit: 1646

FAX: (703) 308-0294

From: Kathryn A. Anderson
Registration no. 32,172

Date: April 17, 2000

Number of Pages (incl. cover sheet): 4

Attorney docket no. 2804-H

MESSAGE:

Re: U.S. Patent Application serial no. 09/079,785
Filed: May 15, 1998
For: CD30 LIGAND OLIGOMERS AND POLYPEPTIDES

CONFIDENTIALITY NOTICE: This communication (including any accompanying page(s)) is intended solely for the use of the individual or entity named above and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient, you are hereby notified that any copying, distribution or other unauthorized use of this communication is prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message to us at the above address via the U.S. Postal Service. Thank you.